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Background: Cervical cancer is a chronic inflammatory disease of multifactorial etiology usually presenting in
sexually active women. Exposure of neoplastic cervical epithelial cells to seminal plasma (SP) has been shown
to promote the growth of cancer cells in vitro and tumors in vivo by inducing the expression of inflammatory
mediators including pro-inflammatory cytokines. IL-1α is a pleotropic pro-inflammatory cytokine induced in several
human cancers and has been associated with virulent tumor phenotype and poorer prognosis. Here we investigated the
expression of IL-1α in cervical cancer, the role of SP in the regulation of IL-1α in neoplastic cervical epithelial cells and the
molecular mechanism underlying this regulation.
Methods and results: Real-time quantitative RT-PCR confirmed the elevated expression of IL-1α mRNA in cervical
squamous cell carcinoma and adenocarcinoma tissue explants, compared with normal cervix. Using immunohistochemistry,
IL-1α was localized to the neoplastically transformed squamous, columnar and glandular epithelium in all cases
of squamous cell carcinoma and adenocarcinomas explants studied. We found that SP induced the expression
of IL-α in both normal and neoplastic cervical tissue explants. Employing HeLa (adenocarcinoma) cell line as a
model system we identified PGE2 and EGF as possible ligands responsible for SP-mediated induction of IL-1α in
these neoplastic cells. In addition, we showed that SP activates EP2/EGFR/PI3kinase-Akt signaling to induce IL-1α
mRNA and protein expression. Furthermore, we demonstrate that in normal cervical tissue explants the induction of IL-1α
by SP is via the activation of EP2/EGFR/PI3 kinase-Akt signaling.
Conclusion: SP-mediated induction of IL-1α in normal and neoplastic cervical epithelial cells suggests that SP may
promote cervical inflammation as well as progression of cervical cancer in sexually active women.
Keywords: Cervical cancer, Seminal plasma, Interleukin-1 alpha, EP2/EGFR/PI3kinase-Akt signaling pathwaysBackground
In sub-Saharan Africa, cervical cancer is the most com-
mon cancer among women accounting for 22.2% of all
cancer cases and also the leading cause of cancer related
deaths in this region [1,2]. Cervical cancer is a disease of
multifactorial etiology usually presenting in sexually ac-
tive women. Recent findings have shown that sexual
transmission and persistent infection of the cervical
epithelium with high risk HPV is the single most com-
mon risk factor for disease development, accounting* Correspondence: kurtjsales@gmail.com; arieh.katz@uct.ac.za
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unless otherwise stated.for approximately 50% of cases [3]. Other risk factors
include, sexually transmitted infections (STIs) [4], im-
munosuppression, and multiple sexual partners [5].
The hallmark of disease pathogenesis is characterized
by chronic inflammatory response in the presence of
underlining neoplasia [6,7].
Characteristically regarded as response to tissue injury
or pathogenic insult, chronic inflammation is typified by
alterations to vascular, epithelial, and immune cell func-
tion [4]. Over the last decade, numerous experimental
studies using gene-disruption and gene over-expression
systems in cell lines, laboratory animals, and tissue explants
have provided evidence to support the role of inflammation
and inflammatory pathways in the pathogenesis and pro-
gression of various human cancers including cervicall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Adefuye et al. Journal of Molecular Signaling 2014, 9:8 Page 2 of 16
http://www.jmolecularsignaling.com/content/9/1/8cancer [8-12]. The inflammatory milieu of most cancer
microenvironment has been shown to consist of tumor
cells, surrounding stromal, immune and inflammatory cells
which all interact intimately to produce cytokines/chemo-
kines, growth factors, and adhesion molecules in a bid to
promote tumorigenesis and metastasis [13]. Of special rele-
vance within this milieu are pro-inflammatory cytokines
which are important mediators of chronic inflammatory re-
sponses, and have cardinal effects on malignant processes.
Interleukin 1α (IL-1α) is a pleotropic pro-inflammatory
cytokine that belongs to the IL-1 family (IL-1α, IL-1β, and
IL-1Ra) gene located on the long arm of chromosome 2
[14]. IL-1α possesses a wide range of inflammatory, im-
munologic and tumorigenic properties [15-17]. IL-1α is se-
creted by a variety of cells including monocytes, tissue
macrophages, neutrophils, fibroblasts, smooth muscle cells,
dendritic cells, and cervical epithelium [15,18,19]. Accumu-
lative evidence suggests that IL-1α plays a crucial role in
tumorigenesis. Within the cancer microenvironment, IL-1α
has been shown to induce the expression of metastatic
genes such as the matrix metalloproteinases (MMPs) and
stimulate the production of angiogenic proteins and growth
factors such as IL-8, IL-6, vascular endothelial growth
factor (VEGF), tumor necrosis factor-α (TNF-α), and trans-
forming growth factor-β (TGFβ) [16,20].
Human Seminal plasma (SP) is a complex organic fluid
comprising of secretions of the cowper’s, littre, prostate,
and the seminal vesicles [21]. Once deposited within the
female reproductive tract (vagina and cervix) during
unprotected coitus, SP has been shown to induce the ex-
pression of several pro-inflammatory cytokines including
IL-1α [22-24]. In sexually active women, the molecular
pathways and degree at which SP normally activates the
expression of these pro-inflammatory components in
any compartment of the female reproductive tract is
poorly understood. SP has been shown to possess an
abundance of pro-inflammatory prostaglandins (PG)
[25] and we and others have shown that cervical cancer
has up-regulated expression of PG receptors [9] which
can be activated by both endogenous and SP-PG. In the
present study, we investigated the role of SP in the regu-
lation of IL-1α expression in normal and neoplastic
cervical epithelial cells and the molecular mechanism
underlying this regulation.
Results
IL-1α is up-regulated in cervical cancer
Prior studies have shown that a major agonist protein of
the interleukin 1 family (i.e. IL-1α) is present in abun-
dance in tumor microenvironment where it plays a
major role in tumourigenesis [14]. In this study, we ini-
tially investigated the expression of IL-1α in normal and
neoplastic cervical tissue explants using real-time quan-
titative RT-PCR (qPCR) (Figure 1A I). Expression of IL-1α transcript was significantly elevated in all cancer tis-
sue samples investigated compared with normal cervical
tissue sample. IL-1α mean relative expression as assessed
by qPCR was 43.65 ± 13.21 fold in neoplastic cervical tis-
sue, while in normal cervical tissue it was 3.488 ± 0.911
(Figure 1A II). The site of IL-1α synthesis in the neo-
plastic tissue was then investigated by immunohisto-
chemistry. IL-1α was localized to the neoplastically
transformed squamous epithelium in squamous cell car-
cinoma (Figure 1B I) and to neoplastically transformed
columnar epithelium lining the endocervical and the glan-
dular epithelium of the endocervical glands in adenocarcin-
omas (Figure 1B IV). In addition, IL-1α immunostaining
was observed in endothelial cells lining the vasculature in
all adenocarcinoma tissue sections investigated (red arrows
in Figure 1B IV). In contrast to the high levels of immuno-
reactive IL-1α observed in cervical cancer tissue, little or no
staining for IL-1α was observed in the normal cervical
tissues (Figure 1B VII). Incubation with biotinylated
IgG in place of primary antibody as control did not
show any immunostaining in carcinoma tissue sections
(Figure 1B X).Seminal plasma induces expression of IL-1α in HeLa
neoplastic cervical epithelial cells
SP has been shown to induce the expression of various
inflammatory cytokines including IL-1α in normal cer-
vical epithelial cells [24]. We hypothesized that SP can
also induce IL-1α expression in neoplastic cervical
epithelial cells, which could potentially enhance cer-
vical inflammation and tumorigenesis. We used a well-
established HeLa (adenocarcinoma) cell line as a
model system to investigate the regulation of IL-1α ex-
pression by SP in neoplastic cervical epithelium. HeLa
S3 cells were treated with vehicle or SP (1:50 dilution)
for 4, 8, 16, and 24 hours and the expression of IL-1α
mRNA assessed using qPCR (Figure 2A). SP signifi-
cantly induced the expression of IL-1α mRNA in HeLa
S3 cells at all-time point investigated. Peak induction
of IL-1α was observed after 4 hours of SP exposure and
was 17.02 ± 4.43 fold increase, while other inductions
were 15.40 ± 4.26, 10.07 ± 5.03, and 8.22 ± 2.68 fold in-
crease for 8, 16 and 24 hours, respectively.
In addition, we investigated IL-α protein expression in
response to SP treatment. Protein lysates extracted from
HeLa S3 cells treated with vehicle or SP (1:50) for 16
and 24 hours, respectively were subjected to ELISA. We
found that SP treatment of HeLa S3 cells significantly
induced the expression of IL-1α protein compared to
the control (Figure 2B; 10.91 ± 2.61 and 8.45 ± 2.36 fold
increase for 16 and 24 hours, respectively). The ELISA
did not detect IL-1α expression in lysate of cells treated
with SP at earlier time points (4 and 8 hours).
Figure 1 Expression of IL-1α mRNA and protein in cervical squamous cell carcinoma, adenocarcinoma and normal cervix. A, Relative
mRNA expression of IL-1α in (I) cervical squamous cell carcinoma (Ca.1-Ca.7, adenocarcinoma (Ca.11), and normal cervix (N1-N8). (II) Mean relative
IL-1α mRNA expression in neoplastic and normal cervical tissue explant as determined by qPCR and shown in (I). B, IL-1α expression by
immunohistochemistry (IHC) staining. I, II, III shows IHC, hematoxylin (HE), and diaminobenzidine (DAB) stain of epithelial cells of squamous
cell carcinoma, respectively. IV-VI shows IHC, HE, and DAB stain of columnar and glandular epithelium of adenocarcinoma, respectively.
VII-IX shows IHC, HE, and DAB stain of normal tissue, respectively. Minimal IL-1α signal was detected in normal cervical tissue (VII and IX).
X-XII is control and shows IHC, HE, and DAB stain of normal tissue, respectively. IL-1α staining was abolished in sections incubated with
the biotinylated secondary antibody alone (negative control) (X and XII). Scale bar, 50 μm. Data represented as mean ± SEM. **, indicates
statistical significance at P < 0.01.
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Figure 2 SP induces IL-1α mRNA and protein expression in HeLa cells. Relative expression of IL-1α mRNA (A) and IL-1α protein (B) in
HeLa cells treated with SP (1:50 dilution) relative to PBS (control) for 4, 8, 16, or 24 hrs as determined by qPCR and ELISA. Data are presented
as mean ± SEM from 5 (A) and 6 (B) independent experiments (n = 5 and 6). Paired T-tests were conducted on the untransformed means of
the replicates between SP and control. *, **, and *** indicates significance at P < 0.05, P < 0.01 and P < 0.001, respectively.
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kinase inhibit SP-mediated induction of IL-1α in HeLa
neoplastic cervical epithelial cells
We next investigated the signal transduction pathways
mediating SP induction of IL-1α mRNA expression,
using PGE receptor 2 (EP2) antagonist and a panel of
small molecule chemical inhibitors of signaling proteins.
HeLa S3 cells were treated with vehicle or SP (1:50)
alone or with EP2 receptor antagonist (AH-6809) or
chemical inhibitors of EGFR (AG-1478), PI3 kinase
(LY-294002), PTGS1 (SC-560), and PTGS2 (NS-398) for
either 4 hours or 16 hours. The expression of IL-1α in
HeLa S3 cells following SP treatment in the presence of
receptor antagonist or chemical inhibitors was deter-
mined by qPCR after 4 hours (Figure 3A and B) and
ELISA after 16 hours (Figure 3C). Figure 3A shows that
EP2 receptor antagonist significantly reduced SP-mediated
induction of IL-1α mRNA in HeLa S3 cells (P < 0.05). SP-
mediated induction of IL-1α was also found to be markedly
reduced in the presence of chemical inhibitors of EGFR
(AG-1478) and PI3 kinase (LY-294002), respectively
(Figure 3B; P < 0.001). Co-incubation of SP with select-
ive PTGS1 (SC-560) and PTGS2 (NS-398) inhibitors
had no inhibitory effect on SP-induced IL-1α mRNA
expression (Figure 3B; P = 0.26 and 0.16, respectively).
This indicates that SP-mediated induction of IL-1α
mRNA expression is via EP2 and EGF receptors and not
via the endogenous PTGS-PG pathway. In addition, co-
treatment with EGTA [calcium chelator; 1.5 mM] and
PD-98059 [ERK inhibitor; 50 μM] did not inhibit SP-
mediated induction of IL-1α (data not shown).
Similarly, data obtained from measuring IL-1α protein
with ELISA (Figure 3C) revealed that AG-1478 and LY-
294002 reduced the expression of SP-induced IL-1α pro-
tein in HeLa S3 cells from 20.42 ± 5.16 fold increase to
8.80 ± 1.89 and 2.00 ± 0.32 fold increases, respectively(P < 0.05 and P < 0.001, respectively). However no signifi-
cant decrease in IL-1α protein secretion was seen in the
presence of NS-398 and SC-560 as compared to SP
(1:50) (Figure 3C; P = 0.17 and P = 0.11, respectively).
These results together demonstrate that SP-mediated in-
duction of IL-1α transcript and protein expression is via
EP2 and EGF receptors and not via the endogenous
PTGS-PG pathway.
PGE2 and EGF induces IL-1α expression in HeLa neoplastic
cervical epithelial cells via their cognate receptors
Human SP is a complex organic fluid comprising of a
vast diversity of antigenically distinct molecules that in-
clude prostaglandins and growth factors [26,27]. We
therefore hypothesized that PGE2 and EGF can induce
IL-1α expression. To investigate the role of PGE2 and
EGF on IL-1α expression, we treated HeLa cells with ve-
hicle or PGE2 [300 nM] or human recombinant EGF
[10 ng/mL] alone or together for 4, 8, 16, and 24 hours
and determined IL-1α mRNA expression using qPCR.
Treatment of HeLa cells with PGE2 (Figure 4A) and
EGF (Figure 4B) resulted in a 2.49 ± 0.66 and 5.76 ± 0.80
maximum fold increase after 8 and 4 hours, respectively.
Treatment of HeLa cells with both PGE2 and EGF to-
gether (Figure 4C) resulted in 2.39 ± 0.52, 6.60 ± 0.63,
16.31 ± 1.23 and 10.88 ± 1.52 fold increase after 4, 8, 16,
and 24 hours, respectively. With peak IL-1α mRNA in-
duction observed after 16 hours treatment (16.31 ± 1.23
fold increase). Furthermore, the inductions of IL-1α
mRNA at 8, 16, and 24 hours by both ligands together
was greater than by each ligand on its own and suggest-
ing that PGE2 and EGF act synergistically in inducing
the increase of IL-1α production by HeLa cells.
The marked inhibition of SP-mediated induction of
IL-1α by the EP2 receptor antagonist AH-6809 and
EGFR kinase inhibitor AG-1478 indicated a role for EP2
Figure 3 IL-1α mRNA and protein expression in HeLa cells is regulated by seminal plasma via the EP2 receptor, EGFR and PI3K pathways.
IL-1α mRNA (A and B) and protein (C) as determined by qPCR and ELISA analysis, respectively. HeLa cells were treated for 4 (A and B) and 16 hours
(C) with seminal plasma (1:50) or vehicle in the absence/presence of EP2 receptor antagonist [AH-6809; 20 μM] and chemical inhibitors to EGFR
kinase [AG-1478; 100 nM], PI3 kinase [LY-294002; 25 μM], PTGS1 [SC-560; 15 μM] or PTGS2 [NS-398; 8 μM]. Data are represented as mean ± SEM
from 5 independent experiments. Paired T-tests were conducted on the untransformed means of the replicates between SP and control and
unpaired T-tests performed on SP versus SP and inhibitor after conversion to fold increases. *, **, and *** indicates significance at P < 0.05, P < 0.01, and
P < 0.001, respectively.
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IL-1α. We next investigated whether IL-1α regulation
was mediated by the EP2 and EGF receptors. In order to
confirm that activation of the EP2 and EGF receptors
can regulate IL-1α expression, we treated HeLa cells
with vehicle or butaprost which is a specific EP2 recep-
tor agonist or human recombinant EGF or both agonist
together for 4, 8, 16 and 24 hours. Activation of EP2
(Figure 4D) receptor significantly induced IL-1α expres-
sion after 8 hours treatment (2.77 ± 0.23) as shown by
qPCR analysis. Co-treatment of HeLa cells with EP2 and
EGF receptor agonists together (Figure 4E) significantly
induced the expression of IL-1α mRNA at all-time
points investigated (Figure 4E; 3.56 ± 1.48, 6.29 ± 1.28,
2.84 ± 0.34, and 2.36 ± 0.75 fold increases). Moreover, the
peak IL-1α induction observed after 8 hours of co-
treatment was greater than either butaprost or EGF
treatment alone suggesting that co-activation of EP2 andEGFR act synergistically in inducing the increase of
IL-1α production by HeLa cells (Figure 4E).
EP2 receptor antagonist, EGFR and PI3 kinase inhibitors
inhibit PGE2 and EGF mediated induction of IL-1α in HeLa
neoplastic cervical epithelial cells
Having demonstrated that PGE2 and EGF induced the
expression of IL-1α in HeLa S3 cells, we next investi-
gated the transduction pathways by which PGE2 and
EGF induce IL-1α expression in HeLa cells. SP was
shown to induce IL-1α expression in HeLa S3 cell via
the EP2/EGFR/PI3 kinase pathways (Figure 3A, B and
C), we thus investigated whether PGE2 and EGF which
are abundant in SP induces the expression of IL-1α in
HeLa cells via similar pathways. HeLa S3 cells were
treated with vehicle or PGE2 alone or in the presence
of AH-6809 and chemical inhibitors, AG-1478 or LY-
294002 for 8 hours and IL-1α mRNA expression was
Figure 4 Induction of IL-1α mRNA in HeLa cells by PGE2 and Butaprost with and without EGF. Induction of IL-1α mRNA in HeLa cells by
PGE2 (A), EGF (B), PGE2 and EGF (C), butaprost (D) and butaprost and EGF (E) as determined by qPCR. HeLa cells were treated for 4, 8, 16 and
24 hours with PGE2 [300 nM] or human recombinant EGF [10 ng/mL] or butaprost [5 μM] or butaprost together with EGF or PGE2 together with
EGF or vehicle as control. Data are represented as mean ± SEM from 5 independent experiments. Paired T-tests were conducted on the untransformed
means of the replicates between PGE2 or EGF or butaprost or butaprost and EGF or PGE2 and EGF treated cells and control. *, ** and *** indicates
significance at P < 0.05, P < 0.01, and P < 0.001, respectively.
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duction of IL-1α (2.49 ± 0.66 fold increase) was signifi-
cantly reduced in the presence of EP2 receptor
antagonist (0.65 ± 0.38) and chemical inhibitors of
EGFR and PI3 kinase (0.91 ± 0.15, and 0.41 ± 0.35 fold
increases, respectively; P < 0.05 in all cases). Subse-
quently, HeLa S3 cells were treated with vehicle, or
PGE2 and EGF alone or in the presence of AH-6809 or
AG-1478 separately or together or with LY-294002 for
16 hours (Figure 5B). Similarly, induction of IL-1α
after treatment with PGE2 and EGF together was
markedly reduced in the presence of EP2 receptorantagonist or EGFR kinase inhibitor, and almost abol-
ished in the presence of EP2 receptor antagonist to-
gether with EGFR inhibitor or in the presence of PI3
kinase inhibitor (P < 0.01 in all cases). In addition, HeLa
S3 cells were treated with vehicle or EGF alone or in the
presence of LY-294002 for 4 hours (Figure 5C). The EGF-
mediated IL-1α induction was reduced from 5.76 ± 0.80
fold increase to 1.88 ± 0.46 fold increase in the presence of
PI3 kinase inhibitor (P < 0.01). These findings confirm that
EGF regulates IL-1α expression via the activation of PI3
kinase pathways, while PGE2 regulates IL-1α expression via
the activation of EP2/EGFR/PI3 kinase pathways.
Figure 5 EP2 antagonist and EGFR and PI3 kinase inhibitors, inhibit PGE2 or PGE2 and EGF or EGF mediated induction of IL-1α in HeLa
cells. EP2 antagonist, EGFR and PI3 kinase inhibitors inhibit PGE2 (A), PGE2 and EGF (B), and EGF (C) mediated induction of IL-1α in HeLa cells as
determined by qPCR. HeLa cells were treated for 4, 8 and 16 hours with EGF [10 ng/mL], or PGE2 [300 nM] or both or vehicle in the absence/presence of
antagonist/inhibitors AH6809 [20 μM], AG1478 [100 nM], AH6809 together with AG1478, and LY294002 [25 μM]. Data are represented as mean ± SEM from
5 independent experiments. Paired T-tests were conducted on the untransformed means of the replicates between ligand/ligands treated cells and control
and unpaired T-tests performed on ligand/ligands versus ligand/ligands and inhibitor after conversion to fold increases. * and ** indicates
significance at P < 0.05 and P < 0.01, respectively.
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kinase signaling to induce IL-1α expression in HeLa
neoplastic cervical epithelial cells
Protein kinase B (Akt) is known to be one of the major
downstream targets of PI3 kinase and upon activation,
Akt moves to the cytoplasm and nucleus where it phos-
phorylates numerous downstream targets involved in the
regulation of various cellular functions [28]. Having
shown that SP mediated the expression of IL-1α in HeLa
cells via the activation of EP2/EGFR/PI3 kinase path-
ways, we investigated the role of SP in the phosphoryl-
ation of Akt and the position of EP2, EGFR, and PI3
kinase pathways in relation to Akt signaling using
immunoblot analysis. HeLa S3 cells were treated with ve-
hicle or SP (1:50 dilution) for 0, 5, 10, 20, 40, 60, 120 and
240 minutes and Akt phosphorylation was measured byimmunoblot analysis. A significant Akt phosphorylation
was observed after 40 minutes with a maximum
phosphorylation at 60 minutes and remaining until
240 minutes post-stimulation with fold increases of
21.58 ± 5.32, 44.64 ± 9.14 and 9.581 ± 2.475, respect-
ively for these time points (Figure 6A) (P < 0.05). We
next treated HeLa S3 cells with vehicle or SP (1:50
dilution) or in the presence or absence of chemical
inhibitors of EGFR kinase (AG 1478), PI3 kinase
(LY294002), and EP2 receptor antagonist (AH6809)
for 60 min and measured Akt phosphorylation. SP-
mediated phosphorylation of Akt was significantly
reduced from fold increase of 8.08 ± 1.688 to fold in-
creases of 1.70 ± 0.23, 3.62 ± 0.08, and 1.00 ± 0.16 in
the presence of AH-6809, AG-1478, and LY-294002,
respectively (P < 0.05) (Figure 6B).
Figure 6 SP induces Akt phosphorylation in HeLa cells. (A) Akt
phosphorylation in HeLa S3 cells treated with SP (1:50) or control for 0, 5,
10, 20, 40, 60, 120, and 240 min. (B) Akt phosphorylation in HeLa cells
treated for 60 min with SP (1:50) or control in the presence/absence of
chemical inhibitors/antagonist EGFR kinase [AG-1478;100 nM], PI3 kinase
[LY-294002; 25 μM] and EP2 antagonist [AH-6809; 20 μM]. Cell lysate
were subjected to immunoblot analysis. Data are represented as
mean ± SEM form 3 independent experiments. Paired T-tests
were conducted on the untransformed means of the replicates between
SP and control and unpaired T-tests performed on SP versus SP and
inhibitor after conversion to fold increases. *indicates P < 0.05.
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EGFR/PI3 kinase activation
Finally we investigated the potential role of SP in the
regulation of IL-1α expression in the cervix and deter-
mined whether SP induces IL-1α expression in the cer-
vix via the same pathways as seen in the HeLa model
cell line. Normal and neoplastic (squamous) cervical tis-
sue explant were treated with vehicle or SP (1:50) for
24 hours and IL-1α mRNA expression was determinedusing qPCR. SP significantly induced the expression of
IL-1α in both neoplastic and normal cervical tissue with
similar fold induction (1.959 ± 0.3226 and 2.124 ± 0.2673
fold increases) (Figure 7A and B). To investigate the sig-
naling pathways by which SP induces IL-1α expression
in the cervix, normal cervical tissue explants were incu-
bated with vehicle or SP (1:50) in the presence or
absence of AH-6809, AG-1478, and LY-290042. qPCR
assessment of IL-1α expression showed a marked reduc-
tion in SP-mediated induction of IL-1α in normal cer-
vical tissue explants in the presence of EP2 receptor
antagonist or the chemical inhibitors of the EGFR (AG-
1478) and PI3 kinase (LY-294002) pathways (P < 0.01 in all
cases) (Figure 7B).
Discussion
Inflammation is a characterized biological response of
vascularized tissues to harmful stimuli, including chem-
ical irritants or microbial pathogens [29]. Over the years,
the role of inflammation as an etiological factor for
cancer has been supported by findings that show that
regular use of non-steroidal anti-inflammatory drugs
(NSAIDs) is associated with reduced incidence of certain
cancers [30]. Hence, inflammatory responses within tumor
microenvironment are now recognized as a critical compo-
nent for tumor progression and one of the major hall-marks
of cancer [31,32]. Despite the numerous experimental and
epidemiological evidence that supports the causal rela-
tionship between inflammation and cancer, the molecular
mechanisms and pathways linking inflammation and can-
cer remain poorly understood [29]. The inflammatory mi-
lieu of most cancer microenvironments consist of various
cells (tumor, surrounding stromal, immune and inflamma-
tory) which all interact intimately to produce cytokines/
chemokines, growth factors, and adhesion molecules in a
bid to promote inflammation, tumorigenesis and metasta-
sis [13]. Of special relevance within this milieu are pro-
inflammatory cytokines which are important mediators of
chronic inflammatory responses, and have cardinal effects
on malignant processes [30] as a result of their direct in-
volvement in carcinogenesis, malignant transformation,
tumor growth, invasion, and metastasis [14].
Cervical cancer is a chronic inflammatory disease and
one of the leading causes of cancer-related death world-
wide with a higher incidence rate reported in under-
developed countries [33]. It is well established that
persistent infection with high-risk HPV is crucial to
disease pathogenesis [34]. However, only a subset of
women infected with high-risk HPV will proceed to
develop invasive cervical cancer, thus suggesting that
other co-factors must be present for the development of
malignancy [7]. Studies have reported an association be-
tween the level of cervical inflammation and the devel-
opment of high grade cervical neoplasia [35] or invasive
Figure 7 SP induces IL-1αmRNA expression in neoplastic and normal cervical tissue explants. SP induce IL-1α mRNA expression in neoplastic
(A) and normal (B) cervical tissue explant. SP induces the expression of IL-1α in normal cervical tissue via the activation of EP2/EGFR/PI3 kinase inflammatory
pathways as determined by qPCR (C). Data represented as mean ± SEM of (n = 12 (A), n = 10 (B) and n = 7 (c), respectively). Paired T-tests were conducted
on the untransformed means of the replicates between SP and control and unpaired T-tests performed on SP versus SP and inhibitor after conversion to
fold increases. *, ** and *** represent significance at P < 0.05, P < 0.01 and P < 0.001, respectively.
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inflammation, but not the actual diagnosis of a specific
sexually transmitted infection is associated with the
development of squamous intraepithelial lesions within
the cervix [37]. Direct links between increased pro-
inflammatory cytokine levels in patients and increasing
grade of cervical intraepithelial neoplasia and invasive
cervical cancer have been established [38].
Using immunohistochemistry and qPCR, this present
study investigated the expression of pro-inflammatory
cytokine IL-1α in normal and neoplastic cervical tissue.
Data presented confirmed the elevated expression of IL-
1α in cervical cancer. This is in agreement with a similar
study by Pao et al. (1995), where it was reported that
neoplastic cervical tissue overtly expresses IL-1α [39]. In
addition, these data suggests a similar pattern of IL-1α
expression in cervical cancer as demonstrated in other ma-
lignancies [40-42]. IL-1α is a pleiotropic pro-inflammatory
cytokine and a member of the IL-1 family. Within the hu-
man body, IL-1α mediates normal physiological functionsranging from induction of vascular permeability and
fever during sepsis to increased secretion of additional
cytokines in autoimmune diseases [30]. The produc-
tion and level of IL-1α expression is elevated in numer-
ous cancers including head and neck [43], breast [40],
pancreatic [44], and gastric cancer [45] and has been
associated with virulent tumor phenotype and poorer
prognosis via the regulation of inflammatory genes and
growth factors to enhance tumor growth and differen-
tiation [46-48] and metastatic potential of cells [49].
Animal studies have further confirmed the role of IL-
1α in tumor development and blood vessel growth
[50]. Similarly, studies by Woodworth et al. [51] and
Castrilli et al. [48] showed that IL-1α promotes in vitro
growth and proliferation of both normal and human
papillomavirus-immortalized and carcinoma-derived
cervical epithelial cells. It is therefore probable that
expression of IL-1α in cervical cancers can act via
similar manner to confer virulent tumor phenotype
and poorer prognosis in these patients.
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uli and recent studies have shown that seminal plasma
can regulate IL-1α expression in the human cervix, post co-
itus [24,52]. Conventionally, human seminal plasma was
regarded primarily as a transport and survival medium for
the mammalian spermatozoa traversing the cervix and the
uterus during and post coitus [26,53]. However, experimen-
tal studies using animal models shows that in addition to
its role as a primary transport medium for the spermatozoa,
seminal plasma also introduce to the female reproductive
tract an array of antigenically distinct signaling molecules
including prostaglandins, several cytokines and growth
factors [26,53-55]. These molecules interact with cognate
receptors on the epithelial lining of the female reproductive
tract to initiate local cellular and molecular changes remin-
iscent of an inflammatory response [26]. These changes are
required for maternal immune adaptation to pregnancy
and for the generation of immune tolerance against fetal
antigens [26,56]. However the molecular pathway by which
seminal plasma mediates the expression of IL-1α and other
cytokines is yet to be fully elucidated. Hence, using HeLa
(adenocarcinoma) cells, normal and neoplastic cervical tis-
sue explants this study investigated the role of SP in the
regulation of IL-1α expression in the cervix and transduc-
tion pathways by which SP induces the expression of IL-1α
in neoplastic and normal cervical epithelium. In addition
this study investigated PGE2 and EGF as possible ligands
mediating SP induction of IL-1α in neoplastic cervical cells.
In the present study we show that exposure of HeLa
neoplastic cervical epithelial cells to SP in vitro increases
the expression of IL-1α. In a similar manner, SP was
found to increase the expression of IL-1α in both normal
and neoplastic cervical tissue explants. This in agree-
ment with studies by Sharkey et al. (2007 and 2012)
where it was reported that SP after deposition into the
female reproductive tract at coitus induces the expres-
sion of pro-inflammatory cytokines including IL-1α in
the cervix [24,52] and initiates an inflammatory re-
sponse. Hence it is likely that in sexually active women
with underlying cervical pathology, recurrent inflamma-
tion consequent of SP-mediated IL-1α expression may
enhance disease progression. Having shown that SP reg-
ulates IL-1α expression in the normal and neoplastic
cervical tissue and epithelial cells, we next investigated
possible signal transduction pathways by which SP medi-
ates this role.
Employing HeLa cell line as a model, we discovered
that SP induced the expression of IL-1α via the EP2 re-
ceptor, EGFR and PI3 kinase pathways since EP2 recep-
tor antagonist (AH6809) and the inhibitors of EGFR
kinase (AG1478) and PI3 kinase (LY294002) inhibited
SP mediated induction of IL-1α in these neoplastic cells.
In contrast, PTGS1 and PTGS2 were not shown to have
a role in the induction of IL-1α by SP, since addition oftheir inhibitors (SC-560 and NS-398, respectively) did
not reduce the induction of IL-1α. In addition, we found
that SP-mediated induction of IL-1α in normal cervical
tissue explant was also inhibited in the presence of the
antagonist and these inhibitors. Similar in vitro studies
by Battersby et al. (2006), Muller et al. (2006) and Sales
et al. (2012) have shown that SP-mediated expression of
pro-inflammatory and angiogenic genes in endometrial
and cervical adenocarcinoma cells was significantly
inhibited in the presence of AH6809 [57] and AG-1478
(EGFR kinase inhibitor) [58,59]. The inhibition of SP-
mediated IL-1α by EP2 antagonist and EGFR kinase
inhibitors suggested that the effects we observed were
mediated by PGE2 and EGF present in the SP.
PGE2 has been established as the predominant PG
found in SP [25]. In the present study, we show that
PGE2-mediated activation of IL-1α occurs via activation
of the EP2, EGFR and Akt pathways. The role of the EP2
receptor in mediating these effects was further con-
firmed using the selective EP2 agonist butaprost. This is
consistent with similar study by Shao et al. (2007) where
it was shown that PGE2, acting via EP2 receptor activate
cAMP/PKA pathway to mediate the expression of IL-1α
in colon cancer cells in an autocrine/paracrine mechan-
ism [18]. EP2 and its signaling have been found to be
up-regulated in cervical cancer [9] and its role in the in-
duction of IL-1α in cervical cancer could explain the
greater expression of IL-1α in cervical cancer tissue ex-
plant relative to normal cervical tissue. These data sug-
gest that PGE2 in SP [26,60,61] can act via its E-series
PGs receptor EP2 receptor to directly transactivate
EGFR via an intracellular signaling mechanism, either by
phosphorylation of cSRC or by the MMP-mediated re-
lease of heparin-bound EGF tethered to the cell mem-
brane, [57,59] leading to IL-1α induction. In addition to
PGE2, SP has been shown to be rich in growth factors
including epidermal growth factor (EGF) [62-64]. Data
presented herein showed that EGF can induce IL-1α in
neoplastic cervical HeLa cells. This in agreement with
similar in vitro study by Hamilton et al. (2003) where it
was shown that EGF induces the expression of pro-
inflammatory cytokine in lung cancer cells, and the ex-
pression of this cytokine was suppressed in the presence
of EGFR inhibitor (AG-1478) [65]. It is therefore very
feasible that the EGFR expressed on the membrane of
these neoplastic cells can be directly activated by EGF in
SP to induce IL-1α expression. The evidence that IL-1α
induction by SP is due to PGE2 and EGF present in SP
is in agreement with findings of Sharkey et al. (2012)
who demonstrated that SP-mediated IL-1α induction in
Ect1 cells occurred independently of TGF-β1, TGF-β2,
and TGF-β3 which are abundant in SP [66].
Furthermore, our data show that concurrent treatment of
HeLa S3 cells with PGE2 and EGF directed a sustained and
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ther ligand alone or butaprost and EGF. Prior study by
Sales et al. (2002) showed that PGE2 significantly in-
duces the expression of EP4 receptor in HeLa cells
[67], increased expression of EP4 receptor in the pres-
ence of EGF could explain the sustained and elevated
increase in IL-1α expression mediated by PGE2 and
EGF in these cells. Furthermore, transactivation of
EGFR via PGE2-EP2 and PGE2-EP4 signaling could
also augment EGF induction. In addition, PGE2 has
been shown to induce the expression of amphiregulin
[68], a ligand for EGFR and activates EGFR signaling.
Taken together, it is likely that the effects of SP on
IL-1α induction may be mediated by a combination of
PGE2 and EGF working in synergy. Once released,
IL-1α can act in an autocrine/paracrine manner within
the site of production to regulate inflammation and
tumorigenesis. Indeed, Shao and colleagues showed in
their study that IL-1α stimulates the migration of colon
cancer cells [18]. It is therefore plausible that in sexu-
ally active women with underlying pre-invasive or in-
vasive cervical condition, repeated exposure of the
elevated EP2 receptor expressed on the neoplastic
cervical epithelial cells [9] to PGE2 present in seminal
plasma could enhance tumorigenesis following ligand-
receptor binding and activation of similar intracellular
signaling pathway to induce IL-1α expression. Expressed
IL-1α can then stimulate cervical cancer cell migration to
adjacent structures within the pelvis and perineum, hence
conferring poor prognosis.
Several studies have shown that PI3 kinase-Akt
signaling is deregulated in many cancers including cer-
vical cancer where amplification of the p110α catalytic
subunit has been reported [69-72]. Interestingly in this
present study, SP and its constituents (PGE2 and EGF)
have been shown to mediate IL-1α expression in neo-
plastic cervical epithelial cells via the activation of
PGE2-EP2-EGFR-PI3 kinase pathways. Once activated
Akt phosphorylates proteins on serine and threonine
residues resulting in the modulation of multiplicity of
downstream substrates, including NF-κB involved in
the regulation of cell proliferation and survival [73-75].
The SP-mediated Akt phosphorylation seen in this
study may act via similar mechanism to induce IL-1α
expression. The SP-mediated induction of a pleotropic
pro-inflammatory cytokine IL-1α in normal and neo-
plastic cervical epithelial cells suggests that SP may
promote cervical inflammation as well as progression
of cervical cancer in sexually active women [58]. Fur-
thermore, this present study is the first to demonstrate
that SP regulates pro-inflammatory cytokine IL-1α
expression in normal and neoplastic cervical cells
via the induction of the EP2-EGFR-PI3 kinase-Akt
pathways.Conclusion
This study identifies PGE2 and EGF within SP as pos-
sible ligands responsible for SP-mediated induction and
secretion of IL-1α in cervical cells. Furthermore, this study
provides evidence for pathways that are used by SP to in-
duce the production of pleotropic pro-inflammatory cyto-
kine IL-1α in normal and neoplastic cervical epithelial cells
following coitus. These pathways are summarized schemat-
ically in Figure 8 and show that SP activates EP2/EGFR/PI3
kinase-Akt signaling pathways to induce IL-1α expression
in cervical cells. The secreted IL-1α can in turn regulate in
an autocrine or paracrine manner through its cognate re-
ceptor the surrounding cells and promote inflammation
and tumorigenesis.Materials and methods
Ethics statement
Ethic approval for this study was obtained from the
University of Cape Town Human Research Ethics
Committee (HREC/REF: 067/2011). Written informed
consent was obtained from all individuals before sample
collection.Chemicals and reagents
Cell culture media, penicillin-streptomycin, and fetal-calf
serum were purchased from Highveld Biological (PTY)
Limited (Cape Town, South Africa). Bovine serum albu-
min (BSA), phosphate buffered saline (PBS), and Trizol®
were all purchased from Sigma Chemical Company
(Cape Town, South Africa). The chemical inhibitors:
AG1478, epidermal growth factor receptor (EGFR) kinase
inhibitor; LY294002, phosphoinositide-3-kinase (PI3K) in-
hibitor; SC560, prostaglandin synthase-1 (PTGS-1) inhibi-
tor; NS398, prostaglandin synthase-2 (PTGS-2) inhibitor;
and PD98059, extracellular signal-regulated kinases 1/2 kin-
ase (ERK1/2) inhibitor were purchased from Calbiochem
(Merck, Darmstadt, Germany). Prostaglandin E2, Butaprost,
PGE2 receptor antagonist (AH6809), and human recombin-
ant epidermal growth factor (EGF) were purchased from
Sigma Chemical Company (Cape Town, South Africa).
Quantikine® Human IL-1α ELISA kit was purchased from
R&D Systems, Minneapolis, USA. Polyclonal goat anti-IL-
1α (sc-1253) and biotin conjugated secondary donkey anti-
goat IgG antibody (sc-2042) were purchased from Santa
Cruz Biotechnology. Streptavidin-biotin peroxidase com-
plex and 3.3’-diaminobenzidine were all purchased from
Dako North America Incorporation, USA. Total PKB (Akt)
(9272 s) and phosphorylated PKB (S473) antibodies were
purchased from Cell Signaling Technology. Pierce® BCA
Protein Assay Kit and SuperSignal® West Pico Chemilumin-
escent Substrates were purchased from ThermoScientific,
Rockford, USA and PVDF membrane was purchased from
GE Healthcare, Amersham, United Kingdom.
Figure 8 Schematic summary highlighting the role of SP and its constituents (PGE2 and EGF) in the regulation of signaling pathway
mediating IL-1α (IL-1 alpha) expression in cervical epithelial cells. Expressed IL-1α can then bind to its cognate receptor, interleukin-1
receptor type I (IL-1RI) to recruit interleukin-1 receptor accessory protein (IL-1RAP) on same cell leading to the activation of IL-1α signaling
pathway (IL-1a pathway).
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Semen was collected from 10 healthy male volunteers at-
tending the Andrology Laboratory of the Reproductive
Medicine unit at Groote Schuur Hospital, Cape Town,
South Africa. All donors had at least 72 hours of total
sexual abstinence (self-reported) prior to ejaculation.
Ejaculates were collected in sterile specimen jars
following a voluntary self-masturbation. Parameters
such as sample volume, sperm number, sperm con-
centration, peroxidase-positive leukocytes, pH and
viscosity were noted and compared with the 2010
WHO (World Health Organization) reference values
for human semen characteristics [76]. Samples with
below average parameters were excluded from the
study. All samples were processed within 30 minutes
of collection. The individual ejaculates were trans-
ported to the laboratory and were pooled. Seminal
plasma (SP) was isolated from the pooled ejaculate
by centrifugation at 15000 g for 20 minutes. Seminal
plasma was then aliquoted (200 μL) and stored at
−80°C until required. Prior to use seminal plasma
was thawed on ice and diluted in sterile filtered
serum free medium to use at a concentration of 1:50. SPhas been shown to exert no toxic effect on HeLa cell
viability up to and including concentration used in this
study [4,77].
Cervical tissue collection and processing
Cervical cancer tissue specimens were obtained at the
time of surgery or biopsy from patients (Ca.1-Ca.18)
who were attending the Gynecologic Oncology Clinic
at Groote Schuur Hospital (Cape Town) and who
had previously been diagnosed with pre or invasive
carcinoma of the cervix. Diagnostic cytology report
was defined according to the Bethesda System for
reporting cervical cytology [78] while pathological
staging was defined according to the revised Inter-
national Federation of Gynecology and Obstetrics
(FIGO) staging for carcinoma of the cervix [79]
upon physical examination. Patient age ranged be-
tween 29–62 years, with a median age of 41 years.
The extent of invasiveness of carcinoma biopsies are
presented in Table 1. Punch biopsies were taken
from the lesion by an experienced gynecologist with
a special interest in gynecology oncology. Samples
were immediately transported in PBS on ice to the
Table 1 Histological typing, extent of invasiveness, and
FIGO staging of carcinoma biopsies
Sample
identification
Histological type FIGO staging
Ca.2-Ca.10,
Ca.12-Ca.15
Squamous carcinoma 0; carcinoma in-situ
Ca.5,Ca.16 Squamous carcinoma IA; moderately differentiated
Ca.1,Ca.17 Squamous carcinoma IA1; moderately differentiated
Ca.11 Adenocarcinoma IB1; well differentiated
Ca.18 Squamous carcinoma IB1; moderately differentiated
Ca.4 Squamous carcinoma IIIB; moderately differentiated
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control and then serum starved overnight prior to stimula-
tion with seminal plasma. Histologically normal cervical
tissues were collected from women (N1-N12) undergo-
ing Wertheim’s hysterectomy for benign gynecological
malignancies at Groote Schuur Hospital (Cape Town).
Patient age ranged between 37–73 years with a median
age of 50.5 years. Cervical (approximately 3 × 4 mm)
tissue samples collected at the time of surgery were im-
mediately transported in PBS on ice to the laboratory
where they were chopped into smaller pieces and di-
vided into experiment and control before being serum
starved overnight prior to SP stimulation.
Cell culture and treatments
HeLa-S3 (HeLa) authenticated and verified as cervical
adenocarcinoma cells positive for HPV-18 sequence with
normal levels of pRB (retinoblastoma) and low levels of
p53 tumour suppressor, were purchased from BioWhit-
taker (Berkshire, UK). Cells were routinely maintained in
DMEM nutrient mixture F-12 with Glutamax-1 and pyr-
oxidine supplemented with 10% fetal bovine serum
(FBS) and 1% penicillin-streptomycin (500 IU/ml peni-
cillin and 500 μg/ml streptomycin) at 37°C and 5% CO2
(v/v). For experiments, HeLa-S3 cells were seeded in
medium supplemented with 10% FBS at density of
2 × 105 cells in 3 cm diameter tissue culture dishes and
allowed to attach and grow overnight after which cells
were serum starved by incubating in serum free medium
for 24 hours. Cells were then treated with vehicle (PBS)
or SP at a dilution of 1:50 or butaprost [5 μM] or PGE2
[300 nM] or EGF [10 ng/ML] for 4, 8, 16, and 24 hours.
For receptor blockade and inhibitor experiments, serum
starved cells were treated with receptor antagonist/in-
hibitors alone or SP (1:50 dilution) alone or together for
4 or 16 hours. The antagonist and inhibitors used and
their final concentrations were: EP2 receptor antagonist
[AH-6809; 20 μM], inhibitors of EGFR [AG-1478; 100 nM],
PI3 kinase [LY-294002; 25 μM], PTGS1 [SC-560; 15 μM],
and PTGS2 [NS-398 8 μM]. The concentrations of
chemical inhibitors used in this study were determinedempirically by titration as described [80-83]. At the concen-
tration and time used, the antagonist or inhibitors showed
no adverse effects on cell viability when stained with 0.4%
trypan blue dye. Fold increases was calculated by dividing
the values obtained from the SP/SP-inhibitor treatments by
the vehicle/vehicle-inhibitor treatments.Real –Time quantitative RT-PCR
Real-time quantitative RT-PCR was performed to deter-
mine the expression of IL-1α in cervical carcinoma biop-
sies and normal cervical tissue and also to assess the
effects of ligands or chemical inhibitors on SP mediated
induction of IL-1α in HeLa S3. RNA was extracted from
neoplastic cervical tissue (adenocarcinoma Ca.11 and
squamous cell carcinoma Ca.1 - Ca.10 and Ca.12 - Ca. 18),
normal cervix (N1-N12), and HeLa S3 cells using
Trizol-reagent as per the manufacturers’ instruction and
reversed transcribed as described previously [10]. Real-time
quantitative RT-PCR reaction was carried out on an Illu-
mina ECO™ quantitative RT-PCR machine and detected
using SYBR green (Bioline, Celtic Molecular, Cape Town,
South Africa) incorporation during PCR reaction. Each
sample was plated in duplicate and a no template control
(H20) was also included. A melt curve was performed for
each PCR reaction and purity of PCR product determined
by a single peak. Glyceraldehyde 3-phosphate dehydrogen-
ase (GAPDH) and Human cyclophilin A (HCYPA) were
included as reference genes in each experiment. These
genes (GAPDH and HCYPA) were the two most stable
genes of all five reference genes (Eukaryotic translation
elongation factor 1 alpha 1 (EEF1A1), actin, β-actin,
GAPDH and HCYPA) analyzed for HeLa S3 and cer-
vical tissue when their average expression stability
value M was calculated using geNorm in qbase + 2.5.1
software (Biogazelle, Belgium). All relative expressions
were calculated using the comparative Ct relative to an
endogenous control of HeLa cell cDNA included in
each experiment. The sequences of IL-1α, GAPDH,
and HCYPA primers used are presented in Table 2.
Data are presented as fold increase as determined by
dividing the relative expression of SP treated group by
that of the control. Data are presented as mean ± SEM.
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Quantikine® Human IL-1α ELISA kit was used to assess
IL-1α protein expression. The experiment was done on
HeLa S3 cells seeded at a density of 5 × 105 in 3 cm tis-
sue culture dishes and serum starved overnight. The
cells were then treated with SP (1:50) or PBS (control)
for 16 and 24 hrs. Cells were lysed as described previ-
ously [10] and total protein quantified using Pierce®
BCA Protein Assay Kit. Expressed cellular IL-1α protein
was determined from the total protein in the lysate. Data
are presented as fold change over control treated, which
was calculated by dividing the amount of IL-1α measured
in SP treated cells at the different time points by the
amount measured in their respective controls. Data are pre-
sented as mean ± SEM of six independent experiments.
SDS-PAGE and Western blot analysis
Immunoblot analysis was performed on solubilized cell
lysates of cultured HeLa cells that were initially sepa-
rated on a 10% SDS-PAGE gel that was run at 100 volts.
Thereafter, separated proteins in the gel were transferred
onto PVDF membrane and subjected to immunoblot
analysis. Membranes were incubated in 10 mL of block-
ing buffer (PBS, 0.1% Tween-20 with 5% w/v nonfat dry
milk) on a shaker for 1 hour at room temperature (RT),
after which membranes were washed three times for 10 mi-
nutes each with 15 mL PBS, 0.1% Tween-20 followed by an
overnight incubation with rabbit anti-PKB (AKT) and anti-
P-PKB (AKT) (1:1000 dilution) at 4°C with gentle shaking.
Thereafter, membranes were washed three times for 10 mi-
nutes each with 15 mL of PBS, 0.1% Tween-20, incubated
for 1 hour with anti-Rabbit HRP-conjugated secondary
antibody (1:5000 dilution) at RT with gentle shaking and
washed again three times with 15 mL PBS, 0.1% Tween-20.
Protein detection was done by chemiluminescence; mem-
branes were incubated with SuperSignal® West Pico Chemi-
luminescent Substrate (1 mL of SuperSignal West Pico
Luminol/Enhancer Solution and 1 mL SuperSignal
West Pico Stable Peroxide Solution) for 5 minutes at
RT and proteins viewed with BioSpectrum™ 500 Imaging
System (Ultra-Violet Products [UVP] Limited, Cambridge,
UK). Densitometry on visualized protein bands was done
using ImageJ version IJ 1.46r (imagej.nih.gov/ij/). Akt phos-
phorylation was calculated by dividing the value ob-
tained from phosphorylated Akt channel by the value
obtained from total Akt channel and expressed as fold
above vehicle controls. Data are presented as mean ± SEM
of three independent experiments.
Immunohistochemistry
Immunohistochemistry was done on archival cervical
blocks (Normal n = 5, squamous cell carcinoma n = 4 and
adenocarcinoma n = 4) obtained from the Department of
Anatomical Pathology, University of Cape Town. Briefly,sections were deparaffinized and rehydrated by immersing
in xylene twice for 5 minutes, 100% ethanol twice for 5 mi-
nute, 95% ethanol for 5 minutes, 70% ethanol for 5 minutes,
50% ethanol for 5 minutes and rinsed with water. Antigen
retrieval was done by pressure cooking for 2 minutes in
0.01 M sodium citrate pH 6. Sections were blocked for en-
dogenous peroxidase by incubating with 3% Hydrogen per-
oxide in methanol on a rocker at RT for 30 minutes and
then rinsed with water followed by 1× TBS (50 mM Tris–
HCl, 150 mM NaCl at pH 7.4). Sections were blocked using
5% normal donkey/goat serum diluted in TBS after which
tissue sections were incubated with polyclonal goat anti-IL-
1α (1:200) antibodies at 4°C for 18 hours. After incubation,
tissue sections were then washed in TBS twice for 5 minutes
each followed by incubation with biotinylated donkey anti-
goat secondary IgG antibody at dilution of 1:500 at RT for
30 minutes. Tissue sections were then further incubated
with streptavidin-biotin peroxidase complex (1:50) at RT
for 30 minutes. Controls were incubated with biotinylated
IgG secondary antibody only. Color reaction was devel-
oped by incubating with 3.3’-diaminobenzidine. Tissue
sections were counterstained in aqueous hematoxylin,
before mounting and coverslipping. Images were visual-
ized and photographed using a Carl Zeiss laser scanning
microscope LSM 510 (Jena, Germany).
Statistical analysis
All data in this study were analyzed by t-test or one-way
ANOVA using Graph Pad Prism 5.0 software (GraphPad
Software Inc., San Diego, CA). Paired T-tests were con-
ducted on the untransformed means of the replicates be-
tween SP and control. Unpaired T-tests were performed
on SP versus SP and inhibitor after conversion to fold in-
creases. One-way ANOVA was used as an additional tool
to determine the significant difference between various
time points for IL-1α by real-time PCR in response to SP.
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